Key Highlights:
- ChrysCapital has completed the acquisition of a 70.68% controlling stake in Novartis India Ltd (NIL), marking a major shift as the company moves under dedicated private equity ownership.
- The deal is ChrysCapital’s first majority-controlled investment in Indian pharma. With NIL’s trusted brands across pain, calcium, gynecology, neurosciences and transplant immunology, the firm aims to build a leading branded-generics platform.
- As NIL begins a new chapter with a new name and identity, Dr. Vikas Gupta takes charge as CEO & MD. Ramesh Ramadurai, Suchita Sharma and Shashank Sinha have also joined the Board as Independent Directors.
Implications:
The acquisition gives ChrysCapital control of a long-established branded-generics platform with trusted brands such as Voveran, Calcium Sandoz and Tegrital, positioning the firm to pursue growth in India’s expanding branded-pharma market. With a 70.68% stake and a new management team led by Dr. Vikas Gupta, the deal could enable sharper portfolio expansion and commercial execution, while future growth will depend on strengthening legacy brands, broadening the portfolio and improving reach across India.
Source: ExpressPharma
